Covered recipient · General Payments record
SHALU NARANG
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
General Payments · PY2019–2025
$23,470.00
- Reported across 40 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,739.41 | 4 |
| Food and Beverage | $601.92 | 10 |
| Travel and Lodging | $124.89 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $6,375.00 | 3 |
| GENZYME CORPORATION | $3,681.60 | 4 |
| Genetix Biotherapeutics Inc | $128.13 | 1 |
| SOBI, INC | $124.63 | 1 |
| DAVOL INC. | $51.36 | 1 |
| Adaptive Biotechnologies Corporation | $24.40 | 1 |
| Astellas Pharma US Inc | $23.97 | 1 |
| Medunik USA Inc. | $22.15 | 1 |
| Day One Biopharmaceuticals | $18.30 | 1 |
| Agios Pharmaceuticals, Inc. | $16.68 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation | $24.40 | 07/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254937215 | CMS |
| Agios Pharmaceuticals, Inc. | $16.68 | 06/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1253244590 | CMS |
| Astellas Pharma US Inc | $23.97 | 10/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238696930 | CMS |
| Davol Inc. | $51.36 | 03/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1232235699 | CMS |
| Day One Biopharmaceuticals | $18.30 | 03/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240088201 | CMS |
| Genetix Biotherapeutics Inc | $128.13 | 12/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1246821600 | CMS |
| GENZYME CORPORATION | $74.27 | 10/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233347376 | CMS |
| GENZYME CORPORATION | $3,364.41 | 10/09/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1233347378 | CMS |
| GENZYME CORPORATION | $124.89 | 10/09/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1233347380 | CMS |
| GENZYME CORPORATION | $118.03 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233347370 | CMS |
| Medunik USA Inc. | $22.15 | 10/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249094192 | CMS |
| PFIZER INC. | $3,250.00 | 04/24/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1230465957 | CMS |
| PFIZER INC. | $2,500.00 | 09/26/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1230466551 | CMS |
| PFIZER INC. | $625.00 | 10/03/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1230473214 | CMS |
| SOBI, INC | $124.63 | 06/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240232865 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.